Expanding early cancer detection with high throughput OCEANA - Ovarian Cancer Exosome Analysis with Nanoplasmonic Array

利用高通量 OCEANA 扩大早期癌症检测 - 使用纳米等离子体阵列进行卵巢癌外泌体分析

基本信息

  • 批准号:
    10762488
  • 负责人:
  • 金额:
    $ 87.76万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-09-19 至 2028-08-31
  • 项目状态:
    未结题

项目摘要

Ovarian cancer (OvCa) remains the most lethal gynecologic cancer in the United States. Early detection through screening, particularly of high-risk populations, is an appealing strategy for timely intervention yet conventional efforts have not improved survival. Extracellular vesicles (EVs; 30-200 nm in diameter) are actively released by cells into circulation, carrying diverse molecular cargo. Capturing this information could provide a real-time window to monitor tumor burden and dynamic molecular changes and potentially OvCa precursor lesions. We aim to advance our translational EV assay for early OvCa diagnosis with a focus on its most lethal subtype, high-grade serous ovarian cancer (HGSOC). We formed a powerful strategic academic-industry alliance between Massachusetts General Hospital, Brigham and Women's Hospital, and Exosome Diagnostics and have laid out two primary objectives. Technology refinement. We will implement an automated and high-throughput platform, OCEANA (Ovarian Cancer Exosomal Analysis with Nanoplasmonic Array). We will also construct an EV marker panel to enhance the diagnostic power of EV assays. Expanded clinical validation. We will rigorously evaluate OCEANA and EV biomarkers using patient-derived organoids and samples across the clinical spectrum (e.g., benign, early, advanced stages) from a world-class and gynecologic-focused biorepository. We have four Specific Aims to achieve these objectives. Aim 1. We will develop a disk-based cartridge for fast, automated total EV isolation. The underlying technology will be our dual-mode chromatography (DMC) which has demonstrated superior EV extraction from plasma. Aim 2. We will establish an expanded EV-marker panel for HGSOC detection informed by patient-derived organoids and EVs. Specifically, EV protein and mRNA results will be combined to make a multi-analyte marker panel. Aim 3. We will analyze EVs from mice hosting HGSOC patient-derived xenografts to study the relationship between tumor progression and circulating EVs. Aim 4. We will screen circulating EVs in women with benign or malignant ovarian conditions, rigorously evaluating OCEANA's clinical performance. Impact. This project will establish OCEANA as a transformative tool for comprehensive EV analyses. The clinical study will also validate EVs as a potent circulating biomarker for early detection of HGSOC. Ultimately, we envision translating the technology as a monitoring tool for cancer care across research and clinical settings.
卵巢癌(OvCa)仍然是美国最致命的妇科癌症。早些时候 通过筛查进行检测,特别是对高危人群进行筛查,是及时进行检测的一项有吸引力的战略。 干预然而,常规的努力并没有提高存活率。细胞外小泡(EVS;30-200 NM)被细胞主动释放到循环中,携带着不同的分子货物。 捕获这些信息可以提供一个实时窗口来监控肿瘤负荷和动态 分子变化和潜在的OvCa前驱病变。我们的目标是推进我们的翻译电动汽车 以高级别浆液性卵巢亚型为重点的OvCa早期诊断方法 癌症(HGSOC)。我们形成了一个强大的战略学术-产业联盟, 马萨诸塞州总医院、布里格姆妇女医院和Exosome诊断和 列出了两个主要目标。技术改造。我们将实施自动化和 高通量平台,SOINA(利用纳米浆阵列进行卵巢癌外切体分析)。 我们还将建造EV标记板,以提高EV检测的诊断能力。已扩展 临床验证。我们将使用患者来源的生物标志物严格评估Ocean和EV生物标志物 临床范围内(如良性、早期、晚期)的有机物和样本 世界一流的、专注于妇科的生物仓库。我们有四个具体的fic目标来实现这些目标。 目标。目标1.我们将开发一种基于磁盘的盒,用于快速、自动地分离全EV。这个 基础技术将是我们的双模式层析(DMC),它已经证明 从血浆中提取优越的电动汽车。目标2.我们将建立一个扩大的EV标记物小组 HGSOC检测由患者衍生的有机化合物和EVS提供信息。肠道病毒的特异性fi、蛋白和基因 结果将被组合成一个多分析物标记面板。目标3.我们将分析老鼠身上的电动汽车 宿主HGSOC患者来源的异种移植物研究肿瘤进展与 流通中的电动汽车。目标4:我们将筛查卵巢良性或恶性患者的循环EVS 条件,严格评估Oceana的临床表现。冲击力。该项目将建立 大洋洲作为全面电动汽车分析的变革性工具。这项临床研究也将验证 EVS可作为早期发现HGSOC的有效循环标志物。最终,我们设想 将这项技术转化为跨研究和临床环境的癌症护理监测工具。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Cesar M Castro其他文献

Cesar M Castro的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Cesar M Castro', 18)}}的其他基金

Composing CODAs to cervical cancer screening through an integrated CRISPR and fluorescent nucleic acid approach
通过集成 CRISPR 和荧光核酸方法将 CODA 应用于宫颈癌筛查
  • 批准号:
    10647930
  • 财政年份:
    2023
  • 资助金额:
    $ 87.76万
  • 项目类别:
High throughput nanoplasmonic exosome testing (NEXT) of immunotherapies in bladder cancer
膀胱癌免疫疗法的高通量纳米等离子体外泌体测试(NEXT)
  • 批准号:
    10463778
  • 财政年份:
    2021
  • 资助金额:
    $ 87.76万
  • 项目类别:
High throughput nanoplasmonic exosome testing (NEXT) of immunotherapies in bladder cancer
膀胱癌免疫疗法的高通量纳米等离子体外泌体测试(NEXT)
  • 批准号:
    10686016
  • 财政年份:
    2021
  • 资助金额:
    $ 87.76万
  • 项目类别:
High throughput nanoplasmonic exosome testing (NEXT) of immunotherapies in bladder cancer
膀胱癌免疫疗法的高通量纳米等离子体外泌体测试(NEXT)
  • 批准号:
    10305371
  • 财政年份:
    2021
  • 资助金额:
    $ 87.76万
  • 项目类别:
Career Enhancement Program (CEP)
职业提升计划(CEP)
  • 批准号:
    10684244
  • 财政年份:
    2020
  • 资助金额:
    $ 87.76万
  • 项目类别:
Dana Farber/Harvard Cancer Center Ovarian Cancer SPORE grant
达纳法伯/哈佛大学癌症中心卵巢癌孢子补助金
  • 批准号:
    10684196
  • 财政年份:
    2020
  • 资助金额:
    $ 87.76万
  • 项目类别:
Dana Farber/Harvard Cancer Center Ovarian Cancer SPORE grant
达纳法伯/哈佛大学癌症中心卵巢癌孢子补助金
  • 批准号:
    10469368
  • 财政年份:
    2020
  • 资助金额:
    $ 87.76万
  • 项目类别:
Career Enhancement Program (CEP)
职业提升计划(CEP)
  • 批准号:
    10469379
  • 财政年份:
    2020
  • 资助金额:
    $ 87.76万
  • 项目类别:
Early Detection through Novel OCEAN Technology - Ovarian Cancer Exosomal Analysis with Nanoplasmonics
通过新型 OCEAN 技术进行早期检测 - 使用纳米等离子体技术进行卵巢癌外泌体分析
  • 批准号:
    9982238
  • 财政年份:
    2018
  • 资助金额:
    $ 87.76万
  • 项目类别:
Early Detection through Novel OCEAN Technology - Ovarian Cancer Exosomal Analysis with Nanoplasmonics
通过新型 OCEAN 技术进行早期检测 - 使用纳米等离子体技术进行卵巢癌外泌体分析
  • 批准号:
    10223236
  • 财政年份:
    2018
  • 资助金额:
    $ 87.76万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 87.76万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 87.76万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 87.76万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 87.76万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 87.76万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 87.76万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 87.76万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 87.76万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 87.76万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 87.76万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了